Clinical trial
Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory…
NCT00284752 · Kaiser Permanente, Other · Completed
Key facts
| NCT number | NCT00284752 |
|---|---|
| Title | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
| Official title | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer |
| Lead sponsor | Kaiser Permanente, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Abraxane |
| Enrollment | 56 |
| Start date | Aug 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Dec 1, 2011 |
| First posted | Feb 1, 2006 |
| Last update posted | Oct 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: